Ziarco is an independent, clinical stage biotechnology company progressing novel & differentiated therapies for inflammatory and allergic diseases, using both oral and topical routes of delivery.

Ziarco has 4 major development programmes staffed by highly experienced drug development professionals.

By exploiting shared pathobiology in inflammatory & allergic pathways, coupled with high human confidence in rationale, Ziarco's programmes can be used to treat multiple disorders affecting the airways, skin and other organs.

Ziarco intends to progress its programmes through clinical proof-of-concept studies using creative drug development strategies and partnerships.